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Background: Scale-up to industrial production level of a fermentation process occurs after optimization at small
scale, a critical transition for successful technology transfer and commercialization of a product of interest. At the
large scale a number of important bioprocess engineering problems arise that should be taken into account to
match the values obtained at the small scale and achieve the highest productivity and quality possible. However,
the changes of the host strain’s physiological and metabolic behavior in response to the scale transition are still not
clear.
Results: Heterogeneity in substrate and oxygen distribution is an inherent factor at industrial scale (10,000 L) which
affects the success of process up-scaling. To counteract these detrimental effects, changes in dissolved oxygen and
pressure set points and addition of diluents were applied to 10,000 L scale to enable a successful process scale-up.
A comprehensive semi-quantitative and time-dependent analysis of the exometabolome was performed to understand
the impact of the scale-up on the metabolic/physiological behavior of the host microorganism. Intermediates from
central carbon catabolism and mevalonate/ergosterol synthesis pathways were found to accumulate in both the 10 L
and 10,000 L scale cultures in a time-dependent manner. Moreover, excreted metabolites analysis revealed that hypoxic
conditions prevailed at the 10,000 L scale. The specific product yield increased at the 10,000 L scale, in spite of
metabolic stress and catabolic-anabolic uncoupling unveiled by the decrease in biomass yield on consumed oxygen.
Conclusions: An optimized S. cerevisiae fermentation process was successfully scaled-up to an industrial scale bioreactor.
The oxygen uptake rate (OUR) and overall growth profiles were matched between scales. The major remaining
differences between scales were wet cell weight and culture apparent viscosity. The metabolic and physiological
behavior of the host microorganism at the 10,000 L scale was investigated with exometabolomics, indicating that
reduced oxygen availability affected oxidative phosphorylation cascading into down- and up-stream pathways
producing overflow metabolism. Our study revealed striking metabolic and physiological changes in response to
hypoxia exerted by industrial bioprocess up-scaling.
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The cultivation of microbial strains over-expressing re-
combinant or native proteins is an established technique
in the biopharmaceutical industry [1]. In this sector, fer-
mentation is normally developed and optimized at small
scale in the laboratory and then scaled up for commer-
cial production. In the transition from the small to the
large scale it is crucial that the productivity and product
qualities remain comparable [2,3]. When this is the case
large quantities of recombinant proteins with thera-
peutic application expressed in microbial organisms can
be produced cost-effectively at high volumetric produc-
tion rate. At the large scale a number of bioprocess en-
gineering problems arise that should be taken into
account to match the values optimized at the small scale
level and achieve the highest productivity and quality
possible.
Among the changes involved in the up-scaling of a
bioprocess are the bioreactor geometry and its volume
capacity, and the physical condition of the culture
medium. Nutrient feeding and aeration in large scale
bioreactors are performed from the top and the bottom,
respectively. The long distances inherent to large scale
bioreactors cause heterogeneity in substrate and oxygen
distribution. Longer mixing time and hydrostatic pres-
sure gradients are produced by greater culture volumes
which in turn affect oxygen transfer rates (OTR) [4].
The challenges brought about by the large scale also
have a relevant impact on cellular physiology and metab-
olism. For example, cells will be exposed to excess nutri-
ent and oxygen limitation on the top, and vice versa at
the bottom. Indeed, spatio-temporal gradients of che-
micals develop in large-scale fed-batch bioreactors [5].
For example, addition of a concentrated and viscous car-
bon source solution at a single point onto the top sur-
face of the growth medium results in long mixing times,
i.e. ≥ 50 s at the 20 m3 scale [6]. Studies using computa-
tional fluid dynamics have shown that considerable glu-
cose gradients are expected when a standard 500 g/L
glucose solution is fed into a 22,000 L bioreactor [7].
These findings have received experimental confirmation,
and it has been further shown that cells were frequently
exposed to peak glucose concentrations in the addition
zone that were several times higher than the mean [5,8]
causing changes in cell metabolism, productivity and
product quality [9-13]. Unlike large reactors, small la-
boratory bioreactors exhibit low mixing times (≤ 5 s)
without significant spatio-temporal variations [14].
Metabolic/physiological responses of cells to environ-
mental heterogeneity can be monitored by highly sensi-
tive “-omics” technologies. Using transcriptomics and
proteomics it has been shown that, under poor mixing
conditions, Escherichia coli cells respond by increasing
transcription and expression of a number of stressproteins that produce inhibition of DNA replication ini-
tiation, and reduction in rRNA synthesis and protein
production in addition to reduced glycolytic activity,
DNA metabolism, and synthesis of structural compo-
nents [5,15]. Recently, a systematic study based on exo-
metabolomics of four biotechnologically relevant model
organisms, E. coli, Bacillus licheniformis, Saccharomyces
cerevisiae, and Corynebacterium glutamicum has been
reported [16]. Time-dependent effects on metabolite
excretion and uptake under conditions of metabolic
overflow happened presumably mediated by transport
mechanisms but not from cell lysis or sampling. These
results are in agreement with the idea that excreted me-
tabolites (exometabolome) reflect the metabolic state of
the cell population [16].
In the present work we address the fundamental ques-
tion of how the physiological and metabolic behavior of
a S. cerevisiae strain producing a recombinant protein
changes in response to the transition from laboratory to
industrial scale, 10,000 L. Specifically, we utilize exometa-
bolomics to determine activation/inactivation of metabolic
pathways and how they affect important physiological
variables such as specific biomass and product yields. In-
sightfully, these analyses allow us to infer specific links be-
tween cell physiology and bioprocess performance at the
manufacturing scale. Our studies describe how a micro-
organism metabolism/physiology is impacted by the up-
scaling of an industrial fermentation process based on a
high-cell density fed-batch culture. Furthermore, we also
show that the strategy described here to approximate the
large scale OTRs to those measured at lab scale can be
used to effectively control the process and to ensure
process robustness and reproducibility in productivity and
product quality.
Results
Performance of the optimized fermentation process at
the small scale
In previous work, we reported the optimization of a S.
cerevisiae high-cell density fed-batch process using a
Bayesian approach [17]. The set points for critical pro-
cess parameters (CPPs), temperature, pH and dissolved
oxygen (DO), were selected based on the high probabil-
ity region calculated to meet the acceptance criteria of
relevant attributes for process performance and product
quality. The selected set points for DO, temperature,
and pH were 12.5%, 29°C, and 5.75, respectively. To
demonstrate the process performance consistency, the
temporal profiles of different attributes from eight
consistency batches running at the small scale (10 L)
were compared. The online process parameter profiles
shown in Figure 1A are the typical profiles seen for the
optimized process. Temperature and pH were well con-
trolled at the set points (data not shown). The DO was
Figure 1 Performance of fermentation consistency runs at the small scale (10 L) bioreactor. Run 1–8 were consistency runs carrying out at
DO 12.5%. (A) Online control of process parameters, DO, air sparge rate and oxygen sparge rate, for Run 1. (B) Wet cell weight (WCW) profiles for
the 8 consistency runs. (C) Broth titer of the recombinant therapeutic protein profiles for the 8 consistency runs. EFT stands for the elapsed
fermentation time.
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pure oxygen supplementation after reaching the max-
imum agitation. The highest pure oxygen sparge demand
was determined to be less than 50% of the total capacity
of 5 standard liters per minute (slpm) by the end of run
(EOR) at elapsed fermentation time (EFT) 80 hr.
Figure 1B shows the wet cell weight (WCW) accumu-
lation as one of the measurements of biomass or relative
volume occupied by cells (also known as volume fraction
εX of cell suspensions), and the consistency of those bio-
mass accumulation profiles among the eight runs. The
WCW increased to around 620 g/kg at approximately
EFT 60 hr and leveled off to ~600 g/kg by the EOR. The
product accumulation profiles were also consistent with
a sustained increase of product concentration (measured
as broth titer) up to the maximum of approximately
1.8 g/L by the EOR (Figure 1C). The quality attributeswere also highly comparable between the batches (see
Table four in [17]). The results indicated that the process
had good controllability for each of the CPPs, and a con-
sistent performance, and hence was ready for scale-up.
Loss of dissolved oxygen control at the large scale
The process was scaled-up from 10 L to large scale
(10,000 L) as described in “Methods” based on matching
the oxygen uptake rate (OUR) exhibited at the 10 L
scale, with the ultimate goal to achieve reproducibility
and consistency in productivity and product quality at
the 10,000 L scale. A trial run, Batch 1, at the 10,000 L
scale was conducted with the same temperature, pH and
DO set points as the 10 L bioreactor. The pure oxygen
sparge rate (FO2) was set at maximum 4,000 slpm while
the total gas flow (FTOT) was set at maximum 5,000
slpm. During the entire incubation time (EFT 80 hr)
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set points 29°C and 5.75, respectively (data not shown).
However, DO was only controlled at set point until EFT
52 hr, and started to drop because the FO2 reached the
maximum 4,000 slpm (Figure 2A). In the attempt to re-
gain DO control, the glucose feed rates were reduced to
decrease the cell oxygen demand. However, a negative
impact on broth titer was observed, i.e. EOR broth titer
decreased from 1.8 g/L to 1.38 g/L (Figure 2C and
Figure 1C). OURs were comparable between the trial
Batch 1 and the 10 L scale runs 5 and 7 up to EFT 35 hr
and after EFT 70 hr, but OURs were not comparable be-
tween EFT 35 hr and 70 hr as seen in Figure 2B.
Another trial run, Batch 2, at the 10,000 L scale was
conducted with the same temperature, pH and DO set
points as Batch 1 while the pure oxygen sparge supply
capacity was increased to equalize FTOT (5,000 slpm).
Beyond the increase of the pure oxygen supply capacity,
there were bolus additions of diluents, i.e., salt feed solu-
tion and water, to maintain DO control. The rationale
was to improve the oxygen mass transfer in the culture,
and to make no modifications to the glucose feed rates
to avoid a drop in productivity by the EOR. The first
bolus supplement of salt solution (~200 L) was added atA
C
Figure 2 Up-scaling the fermentation process at the large (10,000 L)
(10,000 L) scale bioreactor. Run 5 and 7 were consistency runs at DO 12.5%
parameters, DO, air sparge rate and oxygen sparge rate, for Batch 1 and 2,
feed solution. Arrows, “d”, indicates the bolus addition of water. Additional
oxygen sparge supply below 90% of the maximum capacity. (B) OUR com
and broth titer comparison between Batch 1 and 2 at the 10,000 L scale.EFT 59.4 hr over 40 minutes when the pure oxygen
sparge supply reached 90% of the maximum capacity
(“a” arrow, Figure 2D). The second addition of salt solu-
tion (~200 L) was completed over about 90 minutes
when the pure oxygen sparge supply reached 82% of the
maximum capacity at EFT 62.4 hr (“b” arrow, Figure 2D).
The third salt solution addition (~200 L) was started at
EFT 65.4 hr to last about 3.5 hrs to hold the pure oxy-
gen sparge supply around 80% of the maximum capacity
(“c” arrow, Figure 2D). The next addition was water
(~127 L) over about 30 minutes at EFT 69.9 hr (“d”
arrow, Figure 2D), but oxygen supply rate did not drop
as seen with the three previous salt solution additions.
After EFT 70.9 hr additional salt solution was gradually
added until the EOR, to hold the pure oxygen sparge
supply below 90% of the maximum capacity. Conse-
quently, the amount of salt solution added was 4.4 times
the intended amount. The WCW increased to ~700 g/kg
at EFT 60 hr, leveled off during the additions of salt
solution, and finally decreased to ~670 g/kg by the EOR
(Figure 2C). Nevertheless, product titer kept on increasing
during the entire fermentation, albeit, at a slower pace
(Figure 2C). The EOR broth titer was 1.3 g/L which was
marginally decreased with respect to Batch 1.B
D
scale. Batch 1 and 2 were scaled-up and run at DO 12.5% at the large
at the 10 L scale bioreactor. (A and D) Online control of process
respectively. Arrows, “a”, “b” and “c”, indicate the bolus addition of salt
salt solution was gradually added until the EOR, to hold the pure
parison between two scales with Batch 1 and Run 5 and 7. (C) WCW
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improved by the additions of water and salt solution and
pure-oxygen supply capacity increase without modifications
to the profile of glucose feed rates. The process productivity
was still lower than that at the 10 L scale bioreactor.
Differences in mass transfer coefficient, cell relative
volume, and apparent viscosity introduced by scale-up
To evaluate the causes of higher pure oxygen sparge de-
mand in the 10,000 L scale bioreactor, we compared the
mass transfer coefficient (kLa) from both scales. As seen in
Figure 3A, kLa initially increased as the agitation speed was
ramped up from approximately EFT 10 to 34 hr, but then
decreased during the constant maximum agitation speed
irrespective of increasing the supply of oxygen-enriched
air. The kLa temporal profiles had significant changes be-
tween approximately EFT 34 and 54 hr for both scales, but
more pronounced at the 10,000 L scale (Figure 3A). After
EFT 54 hr, the kLa appeared to level off at the 10 L scale,
whereas kLa continued to decrease at lower pace at the
10,000 L scale. By the EOR, kLa dropped to ~2.5 min
−1
and 6.5 min -1 at the 10,000 L and 10 L scale, respect-
ively. The net decrease in mass transfer coefficient was



































Figure 3 Mass transfer coefficient and culture apparent viscosity asse
(10,000 L) scale bioreactor. Run 5 and 7 were consistency runs at DO 12.5% at
between two scales. (B) Apparent viscosity comparison. The apparent viscosit
12.5% was measured at 750 s−1 shear rate as described in “Methods”.When the exhaust gas oxygen concentration was mea-
sured through the on-line mass spectrometry, the oxy-
gen concentration was found to initially decrease until
pure oxygen enrichment of the inlet gas started (ap-
proximately EFT 34 hr) and then continuously increased
up to 80% and 30% oxygen concentration by the EOR at
10,000 L and 10 L scale, respectively (data not shown).
The high oxygen concentration in the exhaust gas to-
wards the EOR at the 10,000 L scale indicates that most
of the oxygen injected to enrich the total inflowing gas
was not efficiently transferred into the culture as reflected
in the low mass transfer coefficient (Figure 3A).
In addition, apparent viscosity measurements of the
culture medium were carried out at different time points
during the fermentation process starting at the Batch 2
and thereafter 10 L scale batches. The apparent viscosity
was low and close to that of water at the start of the
process (data not shown), and increased to the EOR
(Figure 3B). Although the apparent viscosity increased
with the fermentation elapsed time for both scales, the
level of increase was significantly lower at 10 L scale, par-
ticularly after EFT 60 hr. The apparent viscosities were
about 34 centipoises (cP) and 59 cP by the EOR at 10 L
and 10,000 L scale, respectively (Figure 3B). An additional0 60 70 80 90
r)










ssment. Batch 1 was scaled-up and run at DO 12.5% at the large
the 10 L scale bioreactor. (A) Mass transfer coefficient (kLa) comparison
y for the 10,000 L scale Batch 2 and one parallel at 10 L scale run at DO
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fraction occupied by cells measured as WCW; higher
WCWs were observed at 10,000 L scale. Highest WCWs
of 700 g/kg and 620 g/kg were measured at the 10,000 L
and 10 L scale, respectively (Figure 1B and Figure 2C).
Higher WCW and apparent viscosity may have caused the
decrease in kLa observed at 10,000 L scale.
Assuming OTR =OUR at DO set point, if kLa is lower
at the 10,000 L scale, then the driving force (ΔC) must
be increased to maintain the DO (see “Methods”). Con-
sequently, higher pure oxygen supply was demanded by
the culture at 10,000 L scale, and the actual DO concen-
tration in the liquid phase could be lower than the target
set point due to existing oxygen concentration heteroge-
neities inside the large scale bioreactor. The cells were
very likely exposed to lower DO concentrations. There-
fore, the DO and pressure set points were changed to
higher values in the 10,000 L scale as discussed in the
following section.
Performance of the fermentation process with higher
dissolved oxygen at the large scale
To investigate whether the higher DO set point by ele-
vating the average DO concentration inside the 10,000 L
scale bioreactor and higher pressure to enhance the oxy-
gen solubility would reduce the pure oxygen sparge de-
mand, more trial runs were carried out. One trial run,
Batch 3, was kept at the same temperature and pH; but
DO set point was increased to 25% and the backpressure
was doubled to 10 psi. Additions of water and salt solu-
tion as in Batch 2 were also implemented in Batch 3 but
added gradually into the culture together with the glu-
cose and salt feed solution, respectively. The salt feed
program was adjusted to add an extra 94% of salt solu-
tion to the intended volume before process scaling-up.
Effectively the glucose feed was diluted with water by
approximately 13% to cover losses by evaporation. Then
the glucose feed program was adjusted after 52 hr fed-
batch time to deliver the same intended amount of glu-
cose but extended for 2 hrs. As shown in Figure 4A, DO
for Batch 3 was all under control throughout the entire
run. The maximum pure oxygen sparge demand was at
less than 4,000 slpm (80% of the maximal capacity) by
the EOR. Other process parameters such as temperature
and pH were also well controlled (data not shown).
Then two more batches at 10,000 L scale, Batch 4 and 5,
were run in parallel with three 10 L batches, Run 9, 10,
and 11, to continue the verification of process perform-
ance. When the kLa values were compared between
10,000 L scale batches, Batches 3 to 5 exhibited higher
values than 5 min−1 up to approximately EFT 70 hr
(Figure 4B), but Batch 1 values were only above that
value up to approximately EFT 47 hr before the adjust-
ments (Figure 3A). When the kLa values were comparedbetween 10 L and 10,000 L scales, those profiles are
closer than those shown in Figure 3A, indicating that
implemented changes improved kLa values and so the
efficiency to transfer oxygen into the medium.
To further characterize the effect of the implemented
changes on the mixing of the 10,000 L bioreactor, the
agitation speed and the agitator power draw throughout
the fermentation time from batches 3, 4 and 5 were
compared as shown in Figure 4C. Consistently in every
batch, the agitator power draw increased up to 40 kW
(kilowatts) in the approximately first 35 hrs following
the agitation speed ramping-up as required to control
the dissolved oxygen at set point. After EFT 35 hr
the agitation speed remained constant at maximal of
146 rpm until EOR, but the power draw kept increasing
except for the sudden drop at ~ EFT 54 hr (Figure 4C).
The gassed power input per unit of culture volume was
3.85 kW/m3 at EFT 34 hr and 5.54 kW/m3 at EOR.
These high power inputs, compared to those typically
achieved with yeast fermentations in vessels up to
19,000 L or higher scale [12], suggest that the bioreactor
is likely to be well mixed.
To further demonstrate the consistency in cell perform-
ance, we compared the OUR values from 9 batches at the
10 L scale (runs 9 to 17), which were completed with the
changes of pressure and the salt diluents and run in paral-
lel with 10,000 L scale batches, to the 7 batches at
10,000 L scale (batches 4 to 10). As seen in Figure 4D, the
OUR temporal profiles for the two scales became compar-
able. Interestingly, the product accumulation profiles
(broth titer) (Figure 4E) as well as other qualities, purity
by reverse phase-HPLC (RP-HPLC), purity by capillary
iso-electric focusing (cIEF), protease activity, and product-
related 6AA-impurity level by ELISA assay, (data not
shown) were also comparable. The acceptance criteria for
broth titer, and the product quality attributes, such as
purity by RP-HPLC and cIEF, protease activity, and the
6AA-impurity, were established and the related assay de-
scriptions are detailed in our previous work [17]. The
biomass concentration profiles measured by dry cell
weight (DCW) were also comparable between two scales
(Figure 4F), indicating the total number of cells per unit
volume were comparable even though the WCWs were
slightly different (Figure 5A). Taken together, the results
indicate the successful up-scaling of the process after
some fine-tuning adjustments.
Nevertheless, some differences between the two scales
remained, such as WCW, supernatant titer and apparent
viscosity. The WCW temporal profiles were comparable
before EFT 54 hr and diverged thereafter, reaching max-
imum values of 700 g/kg and 600 g/kg at 10,000 L and
10 L scale, respectively (Figure 5A). Interestingly, the
product concentration in the spent medium (supernatant
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Figure 4 Overall consistent fermentation performance between two scales after fine tuning adjustments. Batch 3 was scaled-up and run
at DO 25% and doubled back pressure at the 10,000 L scale bioreactor. Six more batches, Batch 4–10, were completed at the same conditions at
the 10,000 L scale. Nine more runs, run 9–17, were completed in parallel with seven 10,000 L scale batches running at DO 12.5% and doubled
back pressure at the 10 L scale bioreactor. (A) Online process parameters control for 10,000 L scale Batch 3. (B) Mass transfer coefficient comparison
between two scales with Batch 3–5 at the 10,000 L scale and Run 9–11 at the 10 L scale. (C) Agitator power draw and agitation profiles for Batch 3–5
at 10,000 L scale. There was an interrupted gas flow at ~ EFT 37 hr at Batch 4, causing a spike in agitator power draw. (D) OUR comparison between
two scales with 7 batches at 10,000 L scale and 9 runs at the 10 L scale. (E) Broth titer comparison between two scales with 7 batches at 10,000 L scale
and 9 runs at 10 L scale. (F) Dry cell weight (DCW) comparison between two scales with 7 batches at 10,000 L scale and 9 runs at 10 L scale. Error bars
represents “mean +/− one standard deviation”.
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were normalized with respect to its WCWs, the differ-
ences were minimized, showing a high similarity in broth
titer performance (Figure 4E). The apparent viscosity tem-
poral profiles diverged earlier at around EFT 40 hr be-
tween scales, reaching maximum values of 56 cP and
15 cP at 10,000 L and 10 L scale, respectively (Figure 5C).
Metabolite profiling at the small and large scale cultures
To characterize the metabolic behavior of the host strain
of S. cerevisiae at both production scales, we performed
metabolomics of the extracellular medium or exometa-
bolome as described in the “Methods”. The exometabo-
lome represents intracellular metabolism as reflected by
excreted metabolites. Under the production conditions
cell viability was measured by EOR at both scales, 10 L
and 10,000 L, based on the red fluorescence dye, propi-
dium iodide (PI) assay described in the “Methods”. At
both scales the yeast cell viability was maintained in
average slightly above 93%. In addition, the retention of
the Pr-1 protein-encoding plasmid was maintained
above 95% at both small and large scales (data notshown). We focus our analysis at the two scales on
membrane and energetic metabolism including the
mitochondrial functionality.
Mevalonate/ergosterol pathway and membrane
metabolism
Alterations in the mevalonate/ergosterol pathway have been
shown to affect membrane composition and permeability.
These effects could potentially influence the volume occu-
pied by cells as shown in Figure 5A, or trafficking of me-
tabolites through membranes and cell wall. Figure 6
depicts the metabolite profiles from the mevalonate/ergos-
terol pathway obtained at 10 L and 10,000 L production
scales. Concentrations from both ergosterol and its pre-
cursor lanosterol were lower at 10,000 L than at 10 L
scale, but the kinetics of increase was similar (Figure 6A).
However, 3-hydroxy-3-methylglutarate and acetoacetate
increased over time at 10,000 L scale while they decreased
at 10 L scale (Figure 6A). The consistent pattern of
elevated concentrations from upstream metabolites,
3-hydroxy-3-methylglutarate and acetoacetate, and de-
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Figure 5 Performance differences between two scales. Seven batches, Batch 4–10, were completed at DO 25% and doubled back pressure at
the 10,000 L scale bioreactor. Nine runs, run 9–17, were completed in parallel with seven 10,000 L scale batches running at DO 12.5% and
doubled back pressure at the 10 L scale bioreactor. (A) WCW profile comparison between two scales. (B) Product titer measured at the culture
supernatant profile comparison between two scales. (C) Culture apparent viscosity measured at shear rate of 750 s−1 profile comparison between
scales. Only run 12–17 were measured the apparent viscosity at the 10 L scale. Error bars represents “mean +/− one standard deviation”.
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or impaired ergosterol synthesis at the 10,000 L scale
culture (Figure 6B).
Concomitant to changes in ergosterol, the culture
medium at 10,000 L scale exhibited a substantial and
sustained increase in precursors of membrane synthesis
choline, glycerol-3-phosphate (G3P), glycerophospho-
ethanolamine, and glycerophosphorylcholine (GPC), as
compared with 10 L scale (Figure 7A). Conversely, mem-




GPE) were lower in 10,000 L than in 10 L scale (Figure 7A).
These findings suggest a decreased utilization of membrane
building blocks over time in agreement with the idea of a
lower level of membrane biosynthesis in the 10,000 L scalecultures (Figure 7B). Throughout the fermentation, the
profiles of biomass concentration based on DCW mea-
surements were comparable between scales (Figure 4F)
and the levels of precursors for membrane synthesis were
significantly higher at 10,000 L than in 10 L scale. These
results suggest a compromised S. cerevisiae cell membrane
integrity. Furthermore, the compromised membrane in-
tegrity of cells at 10,000 L scale possibly explains the sus-
tained and slow pace increase of WCW compared to 10 L
scale after EFT 54 hr until EOR (Figure 5A).
Glycolysis, tricarboxylic acid (TCA) cycle and
mitochondrial dysfunction
The glycolysis and the TCA cycle belong to the back-
bone central catabolism providing energy in the form of
ATP and reducing equivalents, and key intermediate
precursors for the cellular biomass. These pathways are
AC
B
Sub Pathway Biochemical Name
10L 54hrs 10L 64hrs 10L 76hrs 10L 80hrs 10000L 54hrs 10000L 64hrs 10000L 76hrs 10000L 80hrs
10L 46hrs 10L 46hrs 10L 46hrs 10L 46hrs 10000L 46hrs 10000L 46hrs 10000L 46hrs 10000L 46hrs
Mevalonate metabolism
3-hydroxy-3-methylglutarate 0.7 0.84 0.7 0.66 1.45 1.38 1.54 1.84
mevalonate 0.87 0.51 0.55 0.53 1.1 0.8 0.95 1.13
mevalonolactone 0.88 0.73 0.84 0.7 1.27 1.06 1.14 1.05
Sterol/Steroid
lanosterol 1.42 1.5 1.78 1.88 1.43 1.21 2.47 2.83
ergosterol 1.59 1.93 2.13 2.3 1.76 2.25 3.7 4.07
Figure 6 Pathway diagram and corresponding heat map table and line plot graphs showing biochemical differences in the intermediates
of the mevalonate/ergosterol pathway between scales. (A) Line plot graphs comparison between two scales. (B) Pathway diagram comparison
between two scales. (C) Heat map table comparison between two scales. Red and green arrows show changes in the 10,000 L scale with respect to
that at the 10 L scale. The intermediates measurement and data analysis were determined as described in “Methods”. Error bars represent “mean +/−
one standard deviation”. “M” and “F” in the time axis for every line plot stand for Medium and Feed samples, respectively.
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which was higher at the 10,000 L than the 10 L scale
(Figure 8). Increased medium glucose concentration cor-
related with a notable decrease in glucose-6-phosphate,
fructose-6-phosphate and pyruvate levels from glycolysis.
In contrast, lactate increased in the 10,000 L scale until
EFT 64 hr staying at higher levels than in the 10 L scale.
Interestingly, glycerol-3-phosphate, a membrane lipid
component that can feed into glycolysis at the level
of dihydroxyacetone phosphate, was also significantly
elevated in the 10,000 L scale culture medium (Figure 8).
The results suggest glucose shunt to alternative degrad-
ation pathways. The sustained increase over time of
erythrulose, galactitol, threitol, panose and gluconate is
in agreement with activation of alternative glucose catabol-
ism coupled to metabolite excretion to the medium likelydue to metabolic overflow (Additional file 1: Figure S1).
Taken together, these results indicate that a prominent
difference in glucose catabolism occurs at the two
scales.
The appearance of TCA cycle intermediates in the
medium is considered to reflect impairment in this path-
way as observed in overflow metabolism under aerobic
and glucose excess condition [16]. Citrate levels were
maintained at 10,000 L scale but notably diminished
(significant at EFT 64 hr) at the 10 L scale (Figure 9A).
Fumarate, malate and oxaloacetate increased at EFT
54 hr as compared to EFT 46 hr and kept constant or
augmented over time at the 10,000 L scale. In stark con-
trast, most TCA intermediates were either maintained
or diminished over time at the 10 L scale (Figure 9A and B).





















































































































































Sub Pathway Biochemical Name
10L 54hrs 10L 64hrs 10L 76hrs 10L 80hrs 10000L 54hrs 10000L 64hrs 10000L 76hrs 10000L 80hrs
10L 46hrs 10L 46hrs 10L 46hrs 10L 46hrs 10000L 46hrs 10000L 46hrs 10000L 46hrs 10000L 46hrs
Glycerolipid metabolism
ethanolamine 1.08 1.03 1.34 1.32 1.22 1.35 1.66 1.81
glycerophosphoethanolamine 0.95 1.59 1.6 1.65 1.43 2.23 1.69 1.85
glycerol 0.82 1.12 0.86 0.76 0.86 0.81 0.65 0.61
choline 1.3 1.54 1.57 1.7 1.28 1.45 1.52 1.58
glycerol 3-phosphate (G3P) 1.23 1.73 1.89 1.69 1.05 1.43 1.62 1.63
glycerophosphorylcholine (GPC) 1.44 1.56 1.65 1.74 1.27 1.34 1.55 1.59
Sphingolipid phytosphingosine 1.32 1.21 1.12 1.18 1.02 1.4 2.51 2.77
Lysolipid
1-palmitoleoyl-GPE* 1.77 0.93 1.38 1.4 0.56 0.34 0.8 0.81
1-palmitoyl-GPC 1.84 1.75 2.62 2.76 0.94 1 2.23 2.54
1-palmitoleoyl-GPC* 1.09 0.89 1.16 1.29 1.18 0.78 1.77 1.93
1-palmitoyl-GPI* 1.89 1.61 2.84 2.72 1.59 2.59 4.25 4.85
1-palmitoleoyl-GPI* 2.07 1.85 2.88 2.39 1.79 2.1 4.28 5.25
2-palmitoleoyl-GPI* 1.24 1.13 1.85 2.13 1.08 1.21 2.61 2.95
1-stearoyl-GPI 1.9 2.5 4.24 3.98 1.89 3.54 5.22 5.83
2-stearoyl-GPI* 1.25 1.64 2.98 2.45 1.21 2.13 3.19 3.46
1-oleoyl-GPI* 1.55 1.35 2.39 1.85 1.65 2.04 4.66 5.6
2-oleoyl-GPI* 1.56 1.15 1.77 1.93 0.94 1.24 2.9 3.28
Figure 7 Line plot graphs and corresponding heat map table showing the differences of the glycerolipid membrane precursors and
the membrane lipids between scales. (A) Membrane precursors and membrane lipid comparison between scales. (B) Heat map table
comparison between scales. Blue arrows indicate relationships between precursors and expected membrane synthesis products. The
intermediates measurement and data analysis were determined as described in “Methods”. Error bars represent “mean +/− one standard
deviation”. “M” and “F” in the time axis for every line plot stand for Medium and Feed samples, respectively.
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http://www.microbialcellfactories.com/content/13/1/32TCA cycle overflow leading to loss of intermediates at the
10,000 L scale culture.
Further examination of mitochondrial function at both
scales was performed through analysis of biochemical
markers. An increase in branched chain amino acids,
valine, isoleucine and leucine, and their alpha-keto acid
intermediates are known metabolic indicators of mito-
chondrial dysfunction or respiratory-deficient cells [18,19].
As shown in Figure 10, branched chain amino acids
(valine, isoleucine and leucine) and their alpha-keto acid
intermediates (alpha-keto acids 3-methyl-2-oxobutyrate,
3-methyl-2-oxovalerate and 4-methyl-2oxopentanoate) ei-
ther stayed constant or decreased over time at the 10 Lscale. In contrast, branched chain amino acids were not-
ably elevated in media at the EFT 54 hr at the 10,000 L
scale. These results suggested mitochondrial dysfunction
or impairment that occurred in parallel with accumulation
of glycerol-3-phosphate and intermediates of TCA cycle
and mevalonate pathways. Mitochondrial impairment
could also reflect cell hypoxia at the 10,000 L scale culture
resulting in changes in ergosterol synthesis and glucose
degradation. Importantly, associated with the hypoxia
phenomenon the marked differences in lanosterol and
ergosterol levels found in the 10 L and 10,000 L scale
media at the earliest time point (EFT 46 hr) (Figure 6A),













































































































































Sub Pathway Biochemical Name
10L 54hrs 10L 64hrs 10L 76hrs 10L 80hrs 10000L 54hrs 10000L 64hrs10000L 76hrs 10000L 80hrs
10L 46hrs 10L 46hrs 10L 46hrs 10L 46hrs 10000L 46hrs 10000L 46hrs10000L 46hrs10000L 46hrs
Glycolysis, gluconeogenesis, pyruvate
metabolism
2-isopropylmalate 1.01 1.05 0.93 0.93 1.03 1 0.88 0.83
glycerate 0.77 0.69 1.19 1.1 1.04 1.04 1.05 1.04
glucose-6-phosphate (G6P) 0.89 1.19 0.56 0.79 0.78 1 0.52 0.45
glucose 1-phosphate 0.7 1.21 0.73 0.76 0.8 1.2 1 0.8
glucose 1.19 1.4 1.79 1.58 1.09 1.05 1.09 1.23
1,6-anhydroglucose 1.1 1.2 1.36 1.37 1.23 1.33 1.57 1.69
fructose-6-phosphate 0.8 1.16 0.49 0.66 0.71 0.9 0.37 0.32
fructose 1-phosphate 0.55 0.99 0.19 0.13 0.69 0.82 0.05 0.01
Isobar: fructose 1,6-diphosphate, 
glucose 1,6-diphosphate, myo-inositol
1,4 or 1,3-diphosphate
0.31 0.45 0.09 0.12 0.18 0.19 0.05 0.03
1,3-dihydroxyacetone 1.36 1.12 1.39 1.7 2.22 2.66 4.47 4.8
pyruvate 1.63 0.9 1.09 1.05 1.27 1.31 1.75 2.27
lactate 1.27 1.11 0.92 1.03 1.45 2.03 1.6 1.62
2,3-butanediol 1.31 1.68 1.86 1.92 1.22 1.22 1.79 1.66
Figure 8 Pathway diagram, line plot graphs and corresponding heat map table showing differences in glucose metabolism intermediates
between scales. (A) Line plot graphs comparison between two scales. (B) Pathway diagram comparison between two scales. (C) Heat map table
comparison between two scales. Red and green arrows show changes in the 10,000 L scale with respect to that at the 10 L scale. The intermediates
measurement and data analysis were determined as described in “Methods”. Error bars represent “mean +/− one standard deviation”. “M” and “F” in
the time axis for every line plot stand for Medium and Feed samples, respectively.
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exometabolomics.
Physiological behavior of S. cerevisiae and productivity at
the large scale
As a result of the hypoxia experienced by the S. cerevisiae
cells at the 10,000 L after all implemented modifications,
the decrease in biomass yield on oxygen consumption,
YO2, would be an expected physiological effect. This is
produced by a significant reduction of oxidative phosphor-
ylation in mitochondria, which likely leads to functional
impairment of this organelle. YO2 is an indicator of the de-
gree of coupling between respiration (dissimilation/cata-
bolic pathway) and energy conservation (assimilation/
anabolic pathways) in a microorganism. YO2 often limits
the maximal productivity at which a process can operate
thus influencing the cost of goods. YO2 calculated during
carbon-limited growth for various organisms was found tobe inversely correlated to the higher metabolite product
formation rates [20]. Therefore, the lower the YO2, the
more glucose is converted into the product instead of bio-
mass reflecting a metabolic burden introduced by the
product formation.
The average YO2 at 10,000 L scale was 14% lower
(17.5 g DCW / mol O2; n = 7) than that at 10 L scale
(19.7 g DCW / mol O2; n = 9) (Table 1). The specific rate
of product Pr-1 production (qp; mg Pr-1 / g Gluc/hr)
and the product yield on glucose (Yp; mg Pr-1 / mol
Gluc), as sole and limiting-carbon source, were also cal-
culated. At the 10,000 L scale the average Yp (0.75 mg
Pr-1 / mol Gluc) was approximately 20% higher than at
10 L scale (0.63 mg Pr-1 / mol Gluc) (Table 1). Similarly,
the qp was 16% greater at the 10,000 L than at the 10 L
scale. Taken together, these results constitute proof of
principle that lower biomass yields on molecular (O2)


































































































































Sub Pathway Biochemical Name
10L 54hrs 10L 64hrs 10L 76hrs 10L 80hrs 10000L 54hrs 10000L 64hrs 10000L 76hrs 10000L 80hrs
10L 46hrs 10L 46hrs 10L 46hrs 10L 46hrs 10000L 46hrs 10000L 46hrs 10000L 46hrs 10000L 46hrs
Krebs cycle
citrate 0.68 0.52 0.8 0.85 1.01 0.95 1.12 1.21
2-methylcitrate 0.53 0.35 0.45 0.46 1.15 0.72 0.59 0.58
homocitrate 1.02 0.91 1.02 1.11 1.32 1.16 1.34 1.4
alpha-ketoglutarate 0.34 0.86 0.69 0.4 0.94 0.58 0.39 0.36
succinate 0.8 0.54 0.85 0.84 1.8 0.94 1.15 1.33
fumarate 1.03 1.18 1.06 1.02 1.28 1.28 1.42 1.47
malate 1.06 0.99 1.05 1.08 1.37 1.31 1.54 1.63
oxaloacetate 0.99 0.89 0.85 0.83 1.49 1.39 1.55 1.36
Figure 9 Pathway diagram, line plot graphs and corresponding heat map table showing the differences of TCA intermediates between
scales. (A) Line plot graphs and pathway diagram comparison between two scales. (B) Heat map table comparison between two scales. Red and
green arrows show changes in the 10,000 L scale with respect to that at the 10 L scale. The intermediates measurement and data analysis were
determined as described in “Methods”. Error bars represent “mean +/− one standard deviation”. “M” and “F” in the time axis for every line plot
stand for Medium and Feed samples, respectively.
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http://www.microbialcellfactories.com/content/13/1/32(glucose) into product (recombinant protein). These re-
sults also reaffirm the concept that efficiency from the mi-
croorganism’s physiology/metabolism and the industrial
application viewpoints are not equivalent. Consequently,
we conclude that the hypoxic conditions attained in the
10,000 L scale bioreactor resulted in an increase in process
productivity irrespective of detrimental metabolic and
physiological effects on the host microorganism.Discussion
This work describes the scale-up of a S. cerevisiae
fermentation process from the laboratory to the in-
dustrial scale to produce a recombinant therapeutic
protein. This study shows that oxygen availability is
a key variable determining the successful scale-up of
a fermentation process optimized at the laboratory
scale. Elevations in the WCWs and culture apparent

































































































































TCA cycle fatty acid synthesis
propionyl-CoA acetyl-CoA
Sub Pathway Biochemical Name
10L 54hrs 10L 64hrs 10L 76hrs 10L 80hrs 10000L 54hrs 10000L 64hrs 10000L 76hrs 10000L 80hrs
10L 46hrs 10L 46hrs 10L 46hrs 10L 46hrs 10000L 46hrs 10000L 46hrs 10000L 46hrs 10000L 46hrs
Valine, leucine and isoleucine
metabolism
3-methyl-2-oxobutyrate 0.95 1.03 0.97 0.98 1.42 0.76 0.91 0.85
3-methyl-2-oxovalerate 0.86 1.16 0.8 0.69 1.45 1.41 1.15 0.94
beta-hydroxyisovalerate 1.42 1.01 0.92 0.96 1.26 0.93 0.89 0.82
alpha-hydroxyisocaproate 1.14 1.32 1.66 1.77 1.74 1.86 2.3 2.55
isoleucine 1.06 0.57 0.75 0.62 1.57 0.84 1.37 1.6
leucine 1.03 0.81 0.98 0.78 1.58 1.24 1.67 1.98
N-acetylvaline 1.44 1.76 1.8 2.14 1.99 2.53 3.35 3.4
valine 0.83 0.57 0.73 0.65 1.37 0.82 1.01 1.05
4-methyl-2-oxopentanoate 0.87 1.02 0.82 0.67 1.33 0.88 0.93 0.88
3-hydroxy-2-methylbutyrate 1.05 1.11 1.2 1.1 1.25 1.48 1.78 1.73
alpha-hydroxyisovalerate 0.88 1 1.18 1.26 1.45 1.21 1.43 1.54
isovalerylglycine 1.78 2.62 3.55 3.84 2.56 4.02 6.01 6.83
2-hydroxy-3-methylvalerate 1.3 1.48 1.79 1.94 1.66 1.64 2.13 2.32
citramalate 1.26 1.33 1.51 1.56 1.4 1.43 1.86 1.98
Figure 10 Pathway diagram, line plot graphs and corresponding heat map table showing the changes in branch chain amino acid
levels over time between scales. (A) Line plot graphs and pathway diagram comparison between two scales. (B) Heat map table comparison
between two scales. Red and green arrows show changes in the 10,000 L scale with respect to that at the 10 L scale. The intermediates
measurement and data analysis were determined as described in “Methods”. Error bars represent “mean +/− one standard deviation”. “M” and “F”
in the time axis for every line plot stand for Medium and Feed samples, respectively.
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oxygen transfer efficiency. Changes of process pa-
rameters, such as dissolved oxygen and pressure set
points, and salt solution addition, improved mass
transfer into the culture. But some differences in
above manufacturing attributes remained. Otherfactors, such as heterogeneities in oxygen and nutri-
ent distribution throughout the bioreactor, should
also be considered for process up-scaling [21]. These
changes had a decisive impact on the metabolic
pathways and the physiological behaviour of the
microorganism.
Table 1 Comparison of biomass yields, product yields
and specific rate of product production between the 10 L
and 10,000 L scales
Estimated
response UoM
Average ± one std. dev
10 L scale 10,000 L
(n=9) Scale (n=7)
YO2 g DCW/mol O2 19.7 ± 1.4 17.5 ± 1.1
Yp mg Pr-1/mol Gluc 0.63 ± 0.04 0.75 ± 0.05
qp mg Pr-1/g Gluc/hr 0.043 ± 0.003 0.050 ± 0.003
Ys g DCW/g Gluc 0.39 ± 0.02 0.39 ± 0.01
The biomass yields based on oxygen, YO2, are defined as amount of biomass
(grams of dry cell weight (DCW)) produced per mol of molecular oxygen (O2)
consumed by cells (g DCW / mol O2). The biomass yields based on carbon
substrate, Ys, are defined as amount of biomass (grams of DCW) produced per
gram of glucose fed (g DCW / g Gluc). The product yields based on carbon
substrate, Yp, are defined as amount of secreted product (milligrams of protein
Pr-1) per mol of glucose fed (mg Pr-1 / mol Gluc). The specific rate of therapeutic
protein production, qp, is expressed as milligrams of product Pr-1 per gram of
glucose fed and per hour of elapsed fermentation time (mg Pr-1 / g Gluc/hr). The
average and one standard deviation of every estimated response indicated above
come from 7 batches at 10,000 L scale, or from 9 batches at 10 L scale. UoM: unit
of measurement.
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bioprocess controllability at the large scale
The physico-chemical heterogeneities arising in a “well-
mixed” large-scale bioreactor can cause microorganisms
to alter their physiology in response to challenging en-
vironmental conditions [21,22]. Cell stress responses
controlled by regulatory networks are activated during
adaptation to suboptimal growth conditions and/or
heterologous protein production [23]. However, these
adaptive mechanisms can have a detrimental effect on
the bioprocess related to the control and product quan-
tity/quality in the industrial scale. In previous work we
optimized the S. cerevisiae fermentation process at the
small scale (10 L), using a multivariate Bayesian ap-
proach [17]. As a result, a robust and reproducible
process at the 10 L scale bioreactor was established.
Herein, we describe the scale up of that process, and
characterize the differences between the small and large
scale bioreactors. Decreased mass transfer coefficient
and increased apparent viscosity (Figure 3) and WCW
(Figure 2C) were significant at the large scale culture.
Initially, we supplied higher amounts of pure oxygen
sparge to maintain DO at the 10,000 L scale high-cell
density culture, but the total pure oxygen supply reached
its maximum capacity for Batch 1 at EFT 52 hr
(Figure 2A). Increased culture apparent viscosity and
WCW were two critical variables affected by the scale
up (Figures 2, 3, 4 and 5). High DCW and WCW bio-
masses have been shown to increase the culture apparent
viscosity [24,25]. Also as the viscosity of viscous strepto-
mycete fermentation increased, the oxygen transfer coeffi-
cient (kLa) was observed to decrease [26]. From EFT 35 hr
to the EOR, a three-fold decrease in kLa occurred at thelarge scale (Figure 4) likely due to interfacial blanketing, i.
e. proteins and metabolites adsorption at gas–liquid inter-
faces in bubbles thus reducing gas–liquid area contact.
Consequently, the lower kLa caused the low oxygen avail-
ability, creating hypoxic conditions in the culture. In
addition, the culture at DO 5% exhibited higher WCW
and apparent viscosity than those at DO 36.8% at the 10 L
scale, provoking higher oxygen supply demand (data not
shown). Regaining the DO control at the 10,000 L scale
demanded setting higher DO and pressure set points to-
gether with culture dilution (Figures 2 and 4). The ration-
ale of DO and pressure increases was to improve the
oxygen availability and solubility, thus improving the driv-
ing force, ΔC, for the OTR. On the other hand, kLa can be
increased by additions of salts or be decreased by antifoam
additions [27]. In our production conditions, antifoam has
only a single addition prior to the bioreactor inoculation.
The salt feed starts with the fed-batch and continues to
the end of the process. Although acceptable results in
consistency and reproducibility could be obtained at both
scales (Figure 4), some differences (Figure 5) still persisted
due to the microorganism’s adaptive response to hypoxia.
Exometabolomics or metabolite profiling of the small and
large scale cultures
A comparative, semi-quantitative and time-dependent
analysis of the exometabolome was performed in small
and large scale bioreactors. This analysis revealed that
several metabolites, including those constituting the cen-
tral catabolic backbone of S. cerevisiae, i.e. glycolysis and
TCA cycle, were excreted. A key observation is given by
the apparent impairment of the TCA cycle in mitochon-
dria due to hypoxic conditions in the large scale culture.
The appearance of intermediates from the TCA cycle in
the culture medium constitutes evidence of lack of elec-
tron flow through the respiratory chain, likely provoked
by very low oxygen tensions (Figure 9). Thus, it stalls
the flow through the TCA cycle eliciting intermediates
accumulation followed by their release to the medium.
At the large scale mitochondrial dysfunction would
reverberate into upstream pathways producing overflow
in glycolysis due to lack of pyruvate consumption by
mitochondria; this would explain the increase in
lactate and its excretion together with pyruvate
(Figure 8). Glycolytic overflow can also explain the
glucose shunt to alternative degradation pathways
and the release of galactitol, erythrulose, gluconate
into the culture medium (Additional file 1: Figure
S1). Hypoxia phenomenon is also known to be at the
origin of the diminished ergosterol and lipidic mem-
brane components synthesis. These results indicate
that prevailing oxygen limitation in the large scale
high cell density cultures triggers mitochondrial dys-
function, eliciting overflow in upstream metabolic
Figure 11 Pathway diagram showing the summary of the exometabolomics related to the energy metabolism encompassing
glycolysis, TCA cycle and mitochondrial respiration, and ergosterol and lipid synthesis. Intermediates related to a particular pathway are
color coded. Phosphorylation (ATP), redox (NAD(P)H), Acetyl-CoA intermediates/cofactors with high connectivity are also color coded. Red and
green big arrows show changes in the 10,000 L scale with respect to that at the 10 L scale.
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http://www.microbialcellfactories.com/content/13/1/32pathways such as glycolysis, flux redirection and im-
pairment in lipid synthetic routes that depend on
oxygen availability (Figure 11).In our study the ergosterol precursors, 3-hydroxy-
3-methylglutarate and acetoacetate (Figure 6A) and
membrane precursors, choline, glycerol 3-phosphate,
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level at 10,000 L scale than at 10 L scale, indicating
higher membrane permeability at 10,000 L scale culture.
However, the cell viability remained above 93% for both
scales by the EOR under the production conditions, and
the biomass measured by OD600nm (data not shown) and
DCW were comparable and kept on increasing to the
EOR (Figure 4F), ruling out cell death/lysis. The results
suggest there is no relationship between the appearance
of membrane precursors and the cell viability. Higher
level of membrane precursors at 10,000 L scale culture
may be caused by the hypoxia conditions. From the
changes detected by exometabolomics we conclude that
the microorganism has truly adapted to the stress posed
by the large scale conditions.
Metabolic and physiological behavior of S. cerevisiae high
cell density culture at the large scale
S. cerevisiae is a facultative aerobe that relies on mito-
chondrial respiration for generating energy in the form
of electrochemical gradients and ATP (as illustrated in
Figure 11). Additionally, in the mitochondria TCA cycle
key precursors are generated for synthesis of sterol and
fatty acids, which are main constituents of membrane
assemblies, and affected by lack of oxygen. By transcripto-
mics and proteomics, S. cerevisiae at dissolved oxygen per-
centages of 0.5%, showed global up-regulation of genes
encoding components of the respiratory pathway, and en-
zymes of TCA, resulting in a more efficient energy pro-
duction [28]. The decrease in oxygen availability generates
a large NAD(P)H pool that contributes to stalling meta-
bolic fluxes due to diminished rate of pyridine nucleotides
re-oxidation. This key event cascades in pathways up- and
down-stream producing metabolites overflow and excre-
tion. The TCA cycle and the mevalonate/ergosterol are
among the major downstream pathways affected by low
oxygen at the large scale (Figures 6, 9 and 11). Glycolysis
and glucose shunt to alternative degradation pathways are
among the major upstream affected pathways (Figures 8
and 11).
The diminished re-oxidation of NADH/FADH induces
a TCA cycle overflow indicated by accumulation of oxa-
loacetate, malate, fumarate and citrate; these intermedi-
ates were significantly higher at 10,000 L than 10 L scale
cultures (Figure 9). The lack of pyruvate oxidation into
acetyl-CoA provoked further accumulation of lactate in
the extracellular medium (Figure 8). Elevation of
branched chain amino acids constitutes additional evi-
dence of mitochondrial dysfunction (Figure 10). Epstein
and coworkers [18] reported a comprehensive view of
cellular responses to mitochondrial dysfunction using
cDNA-based microarrays. Their results suggested that
when part of the TCA cycle (succinate oxidation) cannot
proceed in respiratory deficient cells, oxaloacetate andits condensation partner acetyl-CoA must be replenished
stoichiometrically. Many of the up-regulated genes en-
coded for proteins that function: (i) in the conversion of
metabolites generated from the β-oxidation of fatty acids
into intermediates of TCA and glyoxylate cycles, such as
acetyl-CoA, citrate, and succinate, (ii) in the conversion
of pyruvate into oxaloacetate (by pyruvate carboxylase),
(iii) in the conversion of branched-chain amino acids
into acety-CoA and propionyl-CoA (by transaminases).
Furthermore, this transcriptional reorganization to over-
come blocks in the TCA cycle was associated with the
lack of mitochondrial electron transport and therefore
NADH re-oxidation depended on the activities for syn-
thesis of glycerol-3-phosphate, lactate, acetate, and etha-
nol. Our results are in agreement, showing accumulation
of metabolites like glycerol-3-phosphate (from glycolysis
or reduced lipid synthesis), lactate (from glycolysis by
overflow metabolism), valine, isoleucine, leucine (re-
duced branched chain amino acids catabolism), oxaloac-
etate, citrate, malate, fumarate, and precursor for
lipid synthesis (choline, glycerophosphoethanolamine, gly-
cerophosphorylcholine, and glycerol-3-phosphate). In par-
ticular, glycerol-3-phosphate and lactate accumulation
indicate the presence of alternative mechanisms for re-
oxidation of NADH to overcome the reduced mitochon-
drial electron transport by limited availability of oxygen
and/or mitochondrial dysfunction (Figure 11).
Oxygen also intervenes directly in certain synthetic
pathways. One such pathway in yeast is the mevalonate
route that produces ergosterol. Thus, the observed me-
tabolic effects provoked by hypoxia can be explained,
at least in part, by the crucial role played by oxygen
in ergosterol synthesis; this happens from geranyl-
pyrophosphate (geranyl-PP), where four out of six redox
reactions require oxygen (Figure 11). In the same
process, NADPH is also consumed in several reactions.
Additionally, 3 molecules of acetyl-CoA and ATP are re-
quired per molecule of ergosterol synthesized (Figure 11).
Partial inhibition of ergosterol synthesis was suggested
by increased 3-hydroxy-3-methylglutarate synthesis over
time in the 10,000 L scale bioreactor. The change in the
ergosterol synthesis influences membrane composition
and permeability therefore affecting recombinant protein
secretion and protein modification. Furthermore it has
been demonstrated that mutants of S. cerevisiae defect-
ive in synthesis of ergosterol are viable but accumulate
structurally altered sterols within the plasma membrane.
Those results suggested that the membrane disorder and
increasing occurrence of membrane voids within the
plasmatic membrane synergistically enhance passive dif-
fusion [29]. Clearly ergosterol plays an essential role in
bulk membrane function, affecting membrane rigidity,
fluidity, and permeability, so affecting endocytosis and
membrane trafficking [29]. In addition, defective synthesis
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Gas1p (a GPI-anchored α-1, 3-glucanosyltransglycosylate),
to the cell wall [30]. Therefore the reduced Gas1p incorpor-
ation increased cell wall porosity due to reduced β-glucan
crosslinking which might facilitate the passage of heterol-
ogous proteins. The consequences may include less strin-
gent control of the exchange of macromolecules between
cells and surrounding environment, possible including se-
creted proteins whose translocation through the cell is not
affected by ergosterol and sphingolipid depletion [31].
The significant increase of the glycolytic intermediate
glycerol-3-phosphate and lactate reflects metabolic over-
flow in the culture medium at 10,000 L (Figure 8).
Glycerol-3-phosphate is a key precursor of phospho-,
sphingo-, and lysolipids which can explain the changes
in membrane lipid composition and permeability as
reflected by the increase in WCW at the 10,000 L scale
(Figure 5A).
Physiologically, microorganism yield on substrate (car-
bon and O2) and product is a main indicator of how effi-
ciently coupled are the outcome (product and biomass)
and the income (substrate utilization). In an industrial
process, we seek to maintain high product yield that can
be achieved by minimizing biomass and maximizing
substrate utilization and its redirection to the product of
interest. Thus, the metabolic/physiological efficiency for
the microorganism is not equivalent to for the industrial
objectives. Linton and Rye [32] reported data in the in-
dustrial production of exopolysaccharides, indicating
that the highest rates of metabolite production occur in
microorganisms possessing low efficiencies of energy
conservation. It is of utmost industrial importance to
maximize recoverable product per amount of substrate
consumed by the host microorganism for cost-effective
production. Consequently, understanding the bioprocess
parameters that govern microbial growth and product
yields is of fundamental importance for achieving the
successful scale up.
Hypoxia was developed in the large scale bioreactor
under the carbon-limiting fed-batch, high-cell density
culture condition. As an indicator of the degree of coup-
ling between respiration (catabolism) and energy conser-
vation (anabolism), the decrease in YO2 in the 10,000 L
scale cultures revealed less biomass yield per mole of O2
consumed. When we correlated YO2 to qp and Yp, it was
verified that lower YO2 was accompanied by higher rate
of production and level of the product (Table 1). Thus,
at the 10,000 L scale, hypoxia triggers metabolic stress in
S. cerevisiae that results in higher product yield.
A similar impact of hypoxia on the production of a
human Fab fragment expressed in Pichia pastoris has
been reported [31]. These authors attributed the im-
provement in product secretion to the impairment of
cell membrane assembly. Other results regarding fed-batch like conditions for expression of Fab antibody
fragment in E. coli indicated that oxygen-limited condi-
tions promoted Fab accumulation into the extracellular
medium [33]. Herein, in addition to the membrane im-
pairment, we report that mitochondrial oxidative phos-
phorylation, as the primary target of hypoxia, triggers
metabolic overflow decreasing the coupling between res-
piration and anabolism concomitantly with biomass
yield, YO2, but with a positive effect on product yield in
the scaled up process.
Conclusions
Collectively, we showed the successful scale-up of an op-
timized S. cerevisiae fermentation process from the la-
boratory to an industrial bioreactor. Major differences
introduced by the 10,000 L scale that influenced the
process controllability was DO that in turn affected mass
transfer inside the bioreactor. The persistence of differ-
ences in apparent viscosity and wet cell weight, even
after regaining control of the DO as one of the biopro-
cess parameters affected, led us to look into the impacts
from the large scale conditions on the metabolic and
physiological behavior of the host microorganism. The
exometabolomics results indicate that reduced oxygen
availability affected oxidative phosphorylation cascading
into down- and up-stream pathways causing overflow
metabolism. The study provides a striking example of
the impact that stressful culture conditions at the indus-
trial scale may exert on the control and performance of
a bioprocess. Also the metabolic/physiological efficiency
for the microorganism is not equivalent to the industrial
objectives. Consequently, understanding the bioprocess
parameters that govern microbial growth and product
yields is of fundamental importance for achieving the
successful scale up.
Methods
Strain and fermentation process
The S. cerevisiae strain was originally developed from
the parental S. cerevisiae strain AH22 (ATCC 38626)
and the gene encoding for the product is in a high-copy
plasmid. The fermentation process to produce a thera-
peutic recombinant protein, Pr-1, at the small scale
(10 L) was described previously [17]. Briefly, Pr-1 pro-
duction is conditionally induced in the host strain by
glucose limitation that elicits product secretion into the
medium. The fermentation process starts with the in-
oculation of a vial from a working cell bank into a 3 L
disposable baffled Erlenmeyer shake flask (Corning, MA,
US) containing 1 L of defined shake flask medium. This
medium was modified from the buffered minimal
medium (BMM) as described by Goodey et al. [34]. The
culture was incubated and agitated in a rotary shaker at
30°C and 225 rpm until glucose was depleted. The flask
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tor (Biolafitte, Saint Germain en Laye, France) to achieve
higher cell density. The seed medium was similar to the
production medium with the exception of removal of
Tween 80. Both the batch and feed media were modified
from the MW10 medium as described by Goodey et al.
[34]. The modified MW10 feed media were separated
with a glucose nutrient feed and a one-molar (1 M)
phosphate salt solution feed to minimize the salt precipi-
tation. The seed and production bioreactors were con-
trolled by the Distributed Control System (Siemens
Moore APACS, US). DO is controlled at desired set
points (30% at the seed bioreactor, and 12.5% at the pro-
duction bioreactor) by a cascade system of automatically
first ramping up agitation until a maximum (900 rpm),
and continues, if necessary, by injecting pure oxygen be-
ing blend into the inflowing air fixed at a total gas sparge
rate. The pH was controlled at 6.0 and 5.75, for the seed
and production bioreactor, respectively, using ammo-
nium hydroxide (30%) and phosphoric acid (17%) addi-
tions. The temperature was controlled at 29°C. The
backpressure for the seed bioreactor was at 7 psi. The
backpressure for 10 L production cultures was initially
at 5 psi and after the scale-up was increased to 10 psi as
set up at 10,000 L scale conditions. The seed expansion
consisted of a batch phase followed by a fed-batch phase.
Once the target optical density (OD600) of 100 ± 20 was
reached, a portion of the culture was used to inoculate a
10 L production bioreactor with a target inoculation of
OD600 15. Both a glucose nutrient feed and a phosphate
salt solution feed were initiated when glucose concentra-
tion was ≤ 0.3 g/L in the batch medium. Glucose con-
centration was measured offline with a YSI biochemistry
analyzer (YSI, OH, US). OD600, WCW, DCW and vari-
ous other metabolites such as ethanol and acetate were
also monitored. The fermentation process was termi-
nated after 80 hrs of fed-batch time. Fermentation
supernatant samples were collected for checking product
quantity and quality, and metabolite profiling.
Scale-up fermentation process
For scaling-up to a 10,000 L scale bioreactor, a full seed
train was implemented, including shake flask cultures
and seed bioreactors. The seed bioreactor culture was
used to inoculate the 10,000 L scale bioreactor when the
cell density reached the target OD600 of 100 ± 20. The
same seed cultures were also used to inoculate runs 9–
16 at the 10 L scale production bioreactor. The scale-
independent process parameters such as temperature,
pH, DO and backpressure were kept the same as in the
10 L reactors. The backpressure for production bioreac-
tor was initially started at 5 psi and increased to 10 psi.
The DO was initially started at 12.5%, and increased to
25% during the scale-up. The scale-dependent processparameters such as batch volume, glucose nutrient and
phosphate salt feed rates as well as total gas flow rate
were accordingly scaled. The fermentation process was
terminated after 80 hrs of fed-batch time. Fermentation
supernatant samples were collected for analysis of prod-
uct quantity and quality, and metabolite profiling.
Determination of mass transfer coefficient and oxygen
uptake rate
The exhaust gas components were measured online by
mass spectrometer (Model: Prima dB, Thermo Electron
Corporation, Huston, US). Oxygen uptake rate (OUR) is
determined via mass spectrometer using measurements
of O2 percent in the inlet and outlet gas, gas flow rates
and broth volume according to the following formulas:
The total inflowing gas rate is the sum of all flow rates
which pass through the mass flow controllers operated
by the Distributed Control System, including air and
oxygen measured in slpm. The total inflowing gas rate is
thus determined by Equation 1:
FTOT ¼ FAIR þ FO2 ð1Þ
The quantities in millimoles (mmol) per hour of oxy-
gen and carbon dioxide going in were calculated using
Equations 2 and 3. The pure oxygen supply is assumed
to be 100% oxygen. The composition of the air supply is
measured by the mass spectrometer and reported in per-
cent. These percentages are converted into fractions by
dividing by 100. Taking the fraction of oxygen in the air
(ppO2AIR as a fraction 0 to 1) and the fraction of CO2 in
the air (ppCO2AIR as a fraction 0 to 1) to compute:








The flows FO2 and FAIR are in slpm, there are 22.4
standard liters per mole of any ideal gas at 273 K and
1 atm; the equivalencies of 1000 millimoles per mole as
well as 60 min/hr obtain the mmol/hr.
The quantities of oxygen and carbon dioxide coming
out are estimated by applying Equations 4 and 5. The
volume of exhaust gas in slpm is assumed to be equal to
the total volume going in. The composition of the ex-
haust gas is measured by the mass spectrometer. Taking
the fraction of oxygen in the exhaust (ppO2EXH as a frac-
tion 0 to 1) and the fraction of CO2 in the exhaust










The equivalencies of 1000 millimoles per mole and
60 min/hr are the units in mmol/hr.
OUR and carbon dioxide evolution rates (CER) are
normalized by the broth volume as shown in Equations 6
and 7:
OUR ¼ O2IN−O2OUTð Þ
VolBroth
ð6Þ
CER ¼ CO2OUT−CO2INð Þ
VolBroth
ð7Þ
Since the gas quantities are in mmol/hr and broth vol-
ume is in Liters, the units of OUR and CER are mmol/





At steady state operation, the OTR from the gaseous
phase to the liquid phase in a bioprocess is equal to the
cellular OUR. Given that OUR is measured directly via
mass spectrometry, the volumetric mass transfer coeffi-
cient kLa is defined by Equation 9:
kLa ¼ OUR
CO2−CL
  ¼ OUR
ΔC
ð9Þ
The kLa in hr
−1 was converted to min−1.











Considering 21% percent of oxygen in the air (O2INpercent),
and assuming the volume of exhaust gas to be equal to
the total volume going in (which is correct on average),
every term of concentration (C), in mmol/L, is determined







COUTsurf ¼ O2OUTpercentO2Sol ¼ ppO2OUTCO2 ð12Þ
CL ¼ DONETpercentO2Sol ¼ ppO2NETCO2 ð13Þ
Where:
O2OUTpercent = oxygen percent in exhaust by mass
spectrometerFO2 = moving average volumetric flow rate of pure
oxygen in slpm
FAIR = moving average volumetric flow rate of air in
slpm
CL = the net dissolved oxygen (DO) concentration in
the liquid phase
O2Sol = dissolved oxygen concentration in water under
the studied pressure and temperature, also
known as oxygen solubility (CO2)
The logarithmic average value between the inlet and
outlet gas streams was used to calculate the approximate
driving force because the variation in oxygen transfer
driving force ΔC can be significant within a large scale
bioreactor.Analytical methods
Quantification of protein Pr-1 was performed as before
[17]. Broth titer was calculated using the supernatant
titer corrected with WCW. For WCW determination,
10 mL of broth were centrifuged at 10,400 RCF for
35 min; the supernatant was decanted. The resulted pel-
let weight was then divided by the weight of original
broth to get a wet weight value expressed as g/kg of
broth. For DCW determination, 1 mL of broth was cen-
trifuged at 13,000 RCF for 5 min. The supernatants were
collected as spent medium for further analysis. The pel-
let obtained was washed, dried for approximately 18 hr
at 95°C, and the dried pellet weight was divided by the
weight of original broth to get a DCW value expressed
as g/kg of broth.
Culture apparent viscosity was measured using a
Brookfield cone and plate viscometer HA DVII + Pro
(Middleboro, MA) according to the manufacturer’s man-
ual. The measurement was done with a cone and plate
CPE-40 sample cup and spindle at 30, 60 and 100 rpm
to assess the culture rheology characteristics at room
temperature. The shear rate was calculated based on the
rotation speed (rpm) according to: Shear rate (s−1) = 7.5*
N where N is the spindle rotational speed. 30, 60 and
100 rpm corresponded to shear rates of 225, 450 and
750 s−1, respectively. The apparent viscosity was deter-
mined from a single point at shear rate of 750 (s−1) at
room temperature. The resulting apparent viscosity was
reported in centipoises (cP) (as reference for equivalency
with Pascal seconds, 1 cP = 1 mPa · s = 0.001 Pa · s).
The S. cerevisiae cell viability was measured using a
BD FACS Calibur Flow Cytometer (BD Bioscience, San
Jose, CA, US) as described in Garcia et al., [35] and the
manufacturer’s instruction. Samples taken from the cul-
ture were immediately diluted with Phosphate Buffered
Saline (PBS; pH 7.2) to a final concentration of ~106
cells mL−1 and stained with the red fluorescence dye,
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trate the live S. cerevisiae cell membrane, but can pene-
trate the compromised membranes of nonviable cells.




The samples were from 10 L scale identified as runs 9 to
13 and from 10,000 L scale identified as batches 4 to 8. A
total of five media replicates (or spent media) for each scale
were collected at EFT 46, 54, 64, 76 and 80 hr, and used
for metabolite profiling at Metabolon, Inc. (Durham, NC,
US). Additionally, one batch medium sample and one glu-
cose feed sample were included for reference. In total, 52
samples representing 5 time points for 2 reactor scales
(n = 5 each), plus the two reference samples were analyzed.
Sample preparation
Spent medium samples were thawed on ice, and a 100 μL
volume sample was used for extraction. Extraction was
performed by adding 450 μL of methanol, containing re-
covery standards with vigorous shaking for 2 min using
Glen Mills GenoGrinder 2000 (Ops Diagnostics, NJ). The
samples were then centrifuged, supernatant removed
(MicroLab STAR® robotics), and placed briefly on a
TurboVap® (Zymark) to remove the organic solvent. Each
sample was dried under vacuum overnight. Samples were
then prepared for the appropriate instrument, either liquid
chromatography/mass spectrometry/mass spectrometry
(LC/MS/MS) for basic species and acidic species, or gas
chromatography/mass spectrometry (GC/MS).
Liquid chromatography/mass spectrometry and gas
chromatography/mass spectrometry
The LC/MS portion of the platform incorporated a Wa-
ters Acquity UHPLC system and a Thermo-Finnigan LTQ
mass spectrometer, including an electrospray ionization
source and linear ion-trap mass analyzer. Aliquots of the
vacuum-dried samples were reconstituted; one each in
acidic or basic LC-compatible solvents contains 8 or more
injection standards at fixed concentrations (to both ensure
injection and chromatographic consistency). Extracts were
loaded onto columns (Waters UHPLC BEH C18-2.1 ×
100 mm, 1.7 μm) and gradient-eluted with water and 95%
methanol containing 0.1% formic acid (acidic extracts) or
6.5 mM ammonium bicarbonate (basic extracts). Samples
for GC/MS analysis were dried under vacuum desiccation
for a minimum of 18 hrs prior to being derivatized under
nitrogen using bistrimethyl-silyl-trifluoroacetamide. The
GC column was 5% phenyl dimethyl silicone and the
temperature ramp was from 60°C to 340°C over a 17-
minute period. All samples were then analyzed on a
Thermo-Fisher Scientific Trace DSQ fast-scanning single-quadrupole mass spectrometer using electron ionization.
Chromatographic separation followed by full-scan mass
spectra was carried out to record retention time and mo-
lecular weight (m/z) of all detectable ions presented in the
samples. Additionally, on the two LC methods (which are
capable of tandem mass spectrometry), retention time,
molecular weight (m/z), and MS/MS2 fragmentation data
of all detectable ions were recorded.
Compound identification, quantification, and data curation
Metabolites were identified by automated comparison of
the ion features in the experimental samples to a reference
library of over 3000 purified, authenticated chemical
standard entries that include retention time, molecular
weight (m/z), preferred adducts, and in-source fragments
as well as their associated MS/MS2 spectra. In brief, sam-
ples were extracted and split into equal parts for analysis
on the GC/MS and two LC/MS/MS platforms. Proprietary
software was used to match ions to the in-house library of
standards for metabolite identification and for metabolite
quantitation by peak area integration.
Data collection, normalization, and visualization
A client matrix composed of small aliquots of all sample
extracts in this study was created. The client matrix
technical replicate samples were treated independently
throughout the process. All process samples (client
matrix, and a mixture of organic components used to as-
sess GC column performance, process blanks, etc.) were
spaced evenly among the injections for each day and all
samples were randomly distributed throughout each
day’s run. Data were collected over multiple platform
run days and thus, ‘block normalized’ by calculating the
median values for each run-day block for each individual
compound. This minimizes any inter-day instrument
gain or drift, but does not interfere with intra-day sam-
ple variability. Missing values (if any) were assumed to
be below the level of detection for that biochemical with
the instrumentation used and were imputed with the ob-
served minimum for that particular biochemical.
For visualization of biochemical differences between
the various treatment groups, the data are displayed in
line plot graph format. The data selected for display by
line plot were filtered by statistics or included for com-
pletion of a biochemical pathway. An interpretive guide
for this display is shown in Additional file 2: Figure S2A.
Data statistical analyses
Biochemical data were analyzed by Welch’s two-sample
t-tests to test that the means of two independent groups
are equal. The heat map tables are color coded, and de-
scriptions are shown in Additional file 2: Figure S2B. Often
Welch’s correction was applied to allow for unequal vari-
ances between the groups. The p-value relates the
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the observed data; a low p-value (p ≤ 0.05) is generally ac-
cepted as strong evidence that the two means are different.
The q-value describes the false discovery rate; a low q-value
(q ≤ 0.10) is an indication of high confidence in a result.
In the case of the pathway heat map table, this format
is associated with the statistical analysis of the data. Stat-
istical cut-offs are typically employed for determining
candidate metabolites that might be physiologically sig-
nificant in a given study. The relatively conservative cri-
teria of p ≤ 0.05 and q ≤ 0.10 are routinely used in
metabolomic studies, which allows for the identification
of metabolites that are significantly altered in response
to a treatment or significantly different between two
comparison groups and would be expected to yield a
false discovery rate of no more than 10%. For the pur-
poses of this study, comparisons between the various
treatment groups were taken as significant when p ≤
0.05, regardless of the q-value. This approach was taken
in order to be more inclusive of data that otherwise
might not meet the strict statistical cut-off values.
Additional files
Additional file 1: Figure S1. Line plot graphs showing the differences
in glucose metabolism between scales. Red and green arrows show
changes in the 10,000 L scale with respect to that at the 10 L scale. The
intermediates measurement and data analysis were determined as
described in “Methods”. Error bars represent “mean +/− one standard
deviation”.
Additional file 2: Figure S2. Visualization of the metabolite profiling
data in line plot graph and the heat map table. Data are scaled such that
the median value measured across all samples was set to 1.0. A) Line plot
graph. The data for each bioreactor scale is designated as shown (10 L =
green line, 10,000 L = yellow line, basal media “M” = blue point, feed
media “F” = grey point). B) Heat map table analysis. Error bars represent
“mean +/− one standard deviation”.
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